TrialSignal transduction and targeted therapy2024

Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial.

Yaoping Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.